Ocugen

FDA Greenlights Ocugen’s Breakthrough Gene Therapy Trial, Offering New Hope for Stargardt Disease Patients

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced a significant milestone with the U.S. Food and Drug Administration (FDA), gaining alignment to advance its Phase 2/3 pivotal confirmatory trial of OCU410ST, …

FDA Greenlights Ocugen’s Breakthrough Gene Therapy Trial, Offering New Hope for Stargardt Disease Patients Read More

Windtree Therapeutics

Windtree Therapeutics Files Patent Application in India for Istaroxime, Advancing Arrhythmia Treatment

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has filed a national phase patent application with the Indian patent office for its innovative heart failure treatment, Istaroxime. The application, entitled “ISTAROXIME …

Windtree Therapeutics Files Patent Application in India for Istaroxime, Advancing Arrhythmia Treatment Read More